看多

CDXC: Small Float Biopharma with BIG Potential $20

169
After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price.

The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.

It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。